<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04899180</url>
  </required_header>
  <id_info>
    <org_study_id>20-004778</org_study_id>
    <nct_id>NCT04899180</nct_id>
  </id_info>
  <brief_title>Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis</brief_title>
  <official_title>Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis: A Community Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the prevalence of transthyretin cardiac amyloidosis&#xD;
      (TTR-CA) among patients with moderate and severe aortic stenosis in Southeast Minnesota using&#xD;
      99mTc-PYP single-photon positive emission computed tomography with computed tomography&#xD;
      (SPECT/CT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Residents of Southeast Minnesota over 75 years of age with an inpatient or outpatient&#xD;
      diagnosis of moderate or severe aortic stenosis will be consecutively identified using an&#xD;
      automated bi-weekly review of the echo lab calendar (on Mondays and Fridays) at Mayo Clinic&#xD;
      Rochester (MCR) and Mayo Clinic Health System (MCHS) sites. Participants will be consented to&#xD;
      undergo venipuncture, urine collection and 99mTc-PYP SPECT/CT imaging to rule in/out the&#xD;
      diagnosis of TTR-CA. Hence, the prevalence of TTR-CA will be defined. To place this&#xD;
      prevalence in perspective of the global aortic stenosis cohort in the community, a rigorous&#xD;
      screening log will be maintained to allow generation of a comprehensive CONSORT diagram.&#xD;
      Importantly, baseline characteristics of patients who qualify for our study but decline to&#xD;
      consent will still be collected provided that consent for use of their records for medical&#xD;
      research had previously been granted.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of TTR-CA in patients with moderate and severe aortic stenosis</measure>
    <time_frame>Baseline</time_frame>
    <description>Determine the prevalence of Transthyretin Cardiac Amyloidosis in a community based cohort of consecutive patients with moderate or severe aortic stenosis using 99mTc-Pyrophosphate (99mTc-PYP) single-photon positive emission computed tomography with computed tomography (SPECT/CT)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Aortic Stenosis</condition>
  <condition>Transthyretin Amyloidosis</condition>
  <condition>Transthyretin Amyloid Cardiomyopathy</condition>
  <condition>Transthyretin Cardiac Amyloidosis</condition>
  <arm_group>
    <arm_group_label>SPECT/CT</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>99mTc-PYP single-photon positive emission computed tomography with computed tomography</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>99mTc-PYP</intervention_name>
    <description>Radioisotope used by SPECT/CT imaging</description>
    <arm_group_label>SPECT/CT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Resident of Southeastern Minnesota (Olmsted, Dodge, Fillmore, Mower, Freeborn,&#xD;
             Wabasha, or Steele County)&#xD;
&#xD;
          -  Age ≥ 75 years&#xD;
&#xD;
          -  Current diagnosis of moderate or severe aortic stenosis by most recent (within 6&#xD;
             months at most) echocardiogram as defined by:&#xD;
&#xD;
               -  Moderate AS: 1.0 cm2 &lt; aortic valve area (AVA) ≤ 1.5 cm2&#xD;
&#xD;
               -  Severe AS: AVA ≤ 1.0 cm2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any cardiac surgery or major chest trauma within 4 weeks of PYP scan&#xD;
&#xD;
          -  Myocardial infarction within 4 weeks of PYP scan defined by typical angina, EKG&#xD;
             changes and significant change in serial troponins. (Note that chronic troponin&#xD;
             elevation is extremely common in cardiac amyloidosis).&#xD;
&#xD;
          -  Prior or current exposure to Plaquenil (Hydroxychloroquine)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omar F Abou Ezzeddine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carl Griffin, II</last_name>
    <phone>(507) 255-5690</phone>
    <email>GriffinII.Carl@Mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amanda Biddle, R.N.</last_name>
    <phone>(507) 538-5428</phone>
    <email>Biddle.Amanda@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carl Griffin, II</last_name>
      <phone>507-255-5690</phone>
      <email>GriffinII.Carl@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amanda Biddle, R.N.</last_name>
      <phone>(507) 538-5428</phone>
      <email>Biddle.Amanda@mayo.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Omar Abou Ezzeddine</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

